Tesamorelin Cycle vs Continuous: On/Off Protocols, IGF-1 Desensitisation Evidence, and Where to Buy in the UAE (2026)

Why This Question Matters

Tesamorelin is a stabilised GHRH(1–44) analogue developed by Theratechnologies and approved by the FDA in 2010 (brand name Egrifta) for HIV-associated lipodystrophy. Outside the HIV indication, researchers use tesamorelin to study visceral adipose tissue (VAT) reduction, lipid profile, IGF-1 axis modulation, and — more recently — non-alcoholic fatty liver disease (NAFLD/MASH) endpoints.

The cycling question is one of the most contested topics in tesamorelin research: should tesamorelin be administered continuously, or should researchers cycle on and off to "protect" the GHRH receptor and avoid IGF-1 desensitisation? This guide unpacks what the Falutz long-term trials actually show, where the desensitisation hypothesis comes from, and how to source pharmaceutical-grade tesamorelin in the UAE with 24h delivery.

The Falutz Continuous-Dosing Data

Three Falutz-led trials form the evidentiary backbone for continuous tesamorelin dosing. They are unusual in the GHRH-analogue literature because they followed subjects beyond the conventional 12-week window most peptide trials stop at.

Falutz 2007 (NEJM) — 26-week core trial

• n = 412 HIV-positive subjects with excess abdominal fat
• Continuous tesamorelin administration vs placebo, followed for 26 weeks
• VAT reduced 15.2% vs +5.0% placebo (p<0.001)
• IGF-1 rose ~81% and stayed elevated throughout
• No tachyphylaxis observed at week 26

Falutz 2008 (JCEM) — 52-week extension

• Subjects who completed Falutz 2007 continued for an additional 26 weeks
• VAT reduction maintained with continued daily dosing
• Subjects re-randomised to placebo lost the VAT benefit within 26 weeks
• IGF-1 remained elevated in the continuous group at week 52

Falutz 2010 (AIDS) — pooled long-term safety

• Pooled data from two parallel 26-week phase 3 trials with 26-week extension
• Long-term continuous dosing was well tolerated through 52 weeks
• No accumulating receptor desensitisation signal
• Discontinuation predominantly reversed the VAT and IGF-1 effects

The clinical takeaway from Falutz is uncomfortable for cycling proponents: 52 weeks of continuous tesamorelin administration produced sustained pharmacodynamic effect with no demonstrable loss of efficacy. There is no published continuous-vs-cycled head-to-head trial — cycling is folklore, not evidence.

Where the IGF-1 Desensitisation Hypothesis Comes From

The cycling rationale is mostly inherited from three adjacent observations:

1. GHRH receptor downregulation in cell-line studies. In-vitro pituitary somatotroph cultures show receptor internalisation under continuous GHRH stimulation. This is real at the cellular level but does not appear to translate to clinically meaningful pituitary tachyphylaxis in the Falutz trials.
2. Sermorelin / GHRP-2 / GHRP-6 cycling traditions. Bodybuilding-era short-half-life GHRHs and GHRPs (Lee and colleagues described GHRP-6 in the 1980s) developed empirical calendar-based cycling traditions. These were never validated and were largely about cost-management, not pharmacology.
3. The IGF-1 saturation argument. Some researchers argue that maintaining IGF-1 in the upper-normal range continuously may carry hypothetical long-term risks (insulin resistance, theoretical neoplasia risk in those genetically predisposed). The current data do not support a clinical signal in tesamorelin trials but the theoretical concern persists.

None of these three lines of reasoning produced a randomised tesamorelin trial that showed cycling preserves efficacy better than continuous use. The cycling literature for tesamorelin is essentially empirical.

Why Calendar-Based Cycling Lacks Evidence

Enthusiast and bodybuilding-adjacent literature circulates a range of fixed-calendar cycling patterns for GHRH analogues, typically positioned as ways to "protect" receptor sensitivity, manage IGF-1 exposure, or reduce cost. None of these patterns have been tested against continuous administration in a randomised tesamorelin trial, and none are validated by the Falutz or Stanley data reviewed above. REVIVE LAB UAE does not endorse, publish, or provide any such calendar-based pattern.

REVIVE LAB UAE does not provide dosing, cycling, or administration guidance for any compound — that determination sits entirely with the researcher's own institutional protocol. Where a research design calls for comparing continuous versus intermittent exposure, the structure of that comparison — including washout considerations and comparison-arm design — is a matter for the researcher's institutional review process, not a fixed public template.

Reconstitution & Handling Reference

REVIVE LAB UAE does not provide dosing, timing, injection-site, or administration guidance for any compound — that determination sits entirely with the researcher's own institutional protocol. What we can provide is concentration math for lab handling and storage:

• Reconstitution math: Bacteriostatic water; 5 mg vial + 2 mL BAC = 2.5 mg/mL. See our peptide reconstitution guide for concentration math across vial sizes.
• Storage: Reconstituted vials are stability-limited under refrigeration — see our UAE peptide storage guide.
• Published discontinuation data: Falutz 2008 reported that the VAT benefit reversed after subjects were re-randomised off active treatment, indicating the effect is tied to ongoing administration rather than a lasting one-time change. This is a trial finding, not administration guidance.

The IGF-1 Monitoring Argument For Periodic Pauses

Some published research designs favour biomarker-gated decision points over fixed-calendar cycling — using a measurable marker like IGF-1 to inform research-design choices rather than an arbitrary schedule. REVIVE LAB UAE does not provide dosing, cycling, or monitoring-schedule guidance for any compound; the design of any monitoring cadence or pause criteria sits entirely with the researcher's own institutional protocol.

Stanley and colleagues (Stanley 2014 JAMA, Stanley 2019 Lancet HIV) extended the Falutz work into NAFLD endpoints using continuous administration with biomarker monitoring rather than calendar-based cycling. Their NAFLD trial reported a liver fat fraction reduction of roughly 30% in HIV-associated NAFLD over a year of follow-up, with no efficacy decay observed.

UAE Delivery & Sourcing — Where to Buy Tesamorelin in the UAE

REVIVE LAB holds tesamorelin in stock in a Dubai cold-chain warehouse. Researchers ordering tesamorelin from the UAE benefit from no international transit, no customs delay, and no thermal excursion risk during shipping. Same-day Dubai dispatch is standard for orders placed before 4 PM UAE time.

Delivery Windows by Emirate

Why Local UAE Stock Matters for Tesamorelin

• Lyophilised tesamorelin is heat-sensitive in transit. International shipments routinely sit on Gulf tarmacs in summer; local Dubai stock eliminates the worst exposure window.
• Reconstituted vials are 28-day stability-limited at 2–8°C. See our UAE peptide storage guide.
• HPLC certificate per batch. Each REVIVE tesamorelin vial ships with a batch-matched purity certificate.
• UAE-stocked vials, UAE-issued invoice. No cross-border customs paperwork for researchers.

REVIVE Tesamorelin Stock — Confirmed SKUs

• Tesamorelin 5 mg/vial — standard research SKU
• Tesamorelin 10 mg/vial — multi-dose research SKU
• Pair with Bacteriostatic Water 3 mL for reconstitution

Browse the full UAE-stocked range at peptides UAE, or go directly to the tesamorelin product page (buy tesamorelin UAE 24h delivery).

Evidence Summary — Cycle or Continuous?

1. Continuous administration has the strongest evidentiary support. VAT reduction, lipid profile, and NAFLD liver-fat fraction endpoints are all RCT-supported under continuous administration in the Falutz and Stanley trials.
2. Calendar-based cycling has no RCT support. No published human trial shows fixed on/off cycling patterns outperform continuous administration for any tesamorelin endpoint.
3. REVIVE LAB UAE does not provide dosing, cycling, or administration guidance for any compound. That determination sits entirely with the researcher's own institutional protocol, and any research design chosen should be documented and justified per standard research practice.

Practical UAE-Specific Considerations

• Refrigeration during summer power events: Keep reconstituted vials in the main fridge body, not the door, to buffer brief opening/closing thermal swings.
• Travel within GCC: Reconstituted tesamorelin should travel in a cold pack; lyophilised vials tolerate brief room-temperature transit but should be refrigerated on arrival.
• Timing and administration: REVIVE LAB UAE does not provide dosing, timing, or administration guidance for any compound — that determination sits entirely with the researcher's own institutional protocol.

Frequently Asked Questions

Where can I buy tesamorelin in the UAE with 24h delivery?

REVIVE LAB ships tesamorelin 5 mg and 10 mg vials from Dubai stock with 24h delivery across the UAE — same-day to Dubai, next-day to Abu Dhabi, Sharjah, Ajman, RAK and Fujairah. Order before 4 PM UAE time for same-day Dubai dispatch.

Should tesamorelin be cycled or run continuously?

The strongest human evidence (Falutz 2007, 2008, 2010) supports continuous administration for 26 to 52+ weeks with sustained VAT reduction and sustained IGF-1 elevation. No published trial shows on/off cycling outperforms continuous use. Cycling is empirical, not evidence-based. REVIVE LAB UAE does not provide dosing or cycling guidance for any compound — that determination sits entirely with the researcher's own institutional protocol.

Does tesamorelin desensitise the GHRH receptor in humans?

Falutz long-term data through 52 weeks show sustained IGF-1 elevation and sustained VAT reduction with no evidence of pituitary tachyphylaxis. Concerns about receptor desensitisation are theoretical and extrapolated from in-vitro work and other GHRH analogues — not confirmed in tesamorelin clinical trials.

How fast does REVIVE deliver tesamorelin to Abu Dhabi or Sharjah?

Tesamorelin orders to Abu Dhabi ship next-day from REVIVE's Dubai cold-chain warehouse (24h delivery). Sharjah is typically same-day or next-day depending on cut-off time. Tesamorelin is held in stock in the UAE — no international transit, no customs delay.